AU2015206667B2 - Combination-based treatment method - Google Patents

Combination-based treatment method Download PDF

Info

Publication number
AU2015206667B2
AU2015206667B2 AU2015206667A AU2015206667A AU2015206667B2 AU 2015206667 B2 AU2015206667 B2 AU 2015206667B2 AU 2015206667 A AU2015206667 A AU 2015206667A AU 2015206667 A AU2015206667 A AU 2015206667A AU 2015206667 B2 AU2015206667 B2 AU 2015206667B2
Authority
AU
Australia
Prior art keywords
days
inhibitor
topoisomerase
parp
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015206667A
Other languages
English (en)
Other versions
AU2015206667A1 (en
Inventor
Nancy Marie Burns
Deborah H. Charych
Ute Hoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52469293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015206667(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of AU2015206667A1 publication Critical patent/AU2015206667A1/en
Application granted granted Critical
Publication of AU2015206667B2 publication Critical patent/AU2015206667B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2015206667A 2014-01-14 2015-01-13 Combination-based treatment method Active AU2015206667B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461927376P 2014-01-14 2014-01-14
US61/927,376 2014-01-14
US201462080775P 2014-11-17 2014-11-17
US62/080,775 2014-11-17
PCT/US2015/011239 WO2015108876A1 (en) 2014-01-14 2015-01-13 Combination-based treatment method

Publications (2)

Publication Number Publication Date
AU2015206667A1 AU2015206667A1 (en) 2016-07-07
AU2015206667B2 true AU2015206667B2 (en) 2020-05-14

Family

ID=52469293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015206667A Active AU2015206667B2 (en) 2014-01-14 2015-01-13 Combination-based treatment method

Country Status (8)

Country Link
US (2) US10653689B2 (https=)
EP (1) EP3094331B1 (https=)
JP (1) JP6758195B2 (https=)
KR (1) KR102501566B1 (https=)
AU (1) AU2015206667B2 (https=)
CA (1) CA2934552C (https=)
MX (1) MX386070B (https=)
WO (1) WO2015108876A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102611382B1 (ko) 2018-09-19 2023-12-07 삼성디스플레이 주식회사 터치 감지 유닛과 그를 포함하는 표시 장치
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084532A2 (en) * 2006-01-17 2007-07-26 Abbott Laboratories Combination therapy with parp inhibitors
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2009073869A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629696T3 (es) * 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
EP1793830A2 (en) * 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
JP2006124351A (ja) 2004-11-01 2006-05-18 Yakult Honsha Co Ltd 徐放性抗腫瘍剤組成物
TWI426905B (zh) 2006-02-09 2014-02-21 安龍製藥公司 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
ME03396B (me) 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084532A2 (en) * 2006-01-17 2007-07-26 Abbott Laboratories Combination therapy with parp inhibitors
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2009073869A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. MURAI ET AL, "Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib", MOLECULAR CANCER THERAPEUTICS, (2013-12-19), vol. 13, no. 2, pages 433 - 443 *
L. TENTORI, "Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma", THE FASEB JOURNAL, (2006-08-01), vol. 20, no. 10, pages 1709 - 1711 *
S. KUMMAR ET AL, "Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas", CANCER RESEARCH, (2011-09-01), vol. 71, no. 17, pages 5626 - 5634 *
Y. SHEN ET AL, "BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency", CLINICAL CANCER RESEARCH, (2013-07-23), vol. 19, no. 18, pages 5003 - 5015 *

Also Published As

Publication number Publication date
CA2934552C (en) 2021-03-30
MX386070B (es) 2025-03-18
EP3094331A1 (en) 2016-11-23
US20160339013A1 (en) 2016-11-24
MX2016009167A (es) 2016-09-09
KR102501566B1 (ko) 2023-02-17
US10653689B2 (en) 2020-05-19
KR20160106086A (ko) 2016-09-09
EP3094331B1 (en) 2017-12-27
US20200237747A1 (en) 2020-07-30
JP2017502091A (ja) 2017-01-19
CA2934552A1 (en) 2015-07-23
WO2015108876A1 (en) 2015-07-23
AU2015206667A1 (en) 2016-07-07
JP6758195B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
US10786552B2 (en) Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
US20200237747A1 (en) Combination-based treatment method
JP2023099731A (ja) ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
EP2771034B1 (en) Topoisomerase-i and-ii inhibitors for use in the treatment of patients suffering from cancer
MX2015006733A (es) Metodo para evaluar y predecir la eficacia del tratamiento del cancer de mama con un inhibidor de topoisomerasa de accion prolongada.
CN109789136B (zh) 用于预防或治疗结肠直肠癌的药物联合组合物
Xiang et al. A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience
Zhao EZN-2208 (PEG-SN38), a 40 kda polyethylene glycol (peg) conjugate, as an anticancer agent: review of preclinical and clinical data
CA3000211C (en) Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
HK40056474A (en) Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
US20170173070A1 (en) Methods of administering lmwh
CN107281181A (zh) 埃替格韦减轻伊立替康毒性的医药新用途
HK1253347B (en) Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)